vs
PREFORMED LINE PRODUCTS CO（PLPC）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是Vericel Corp的1.9倍（$173.1M vs $92.9M），Vericel Corp净利率更高（25.0% vs 4.9%，领先20.1%），Vericel Corp同比增速更快（23.3% vs 3.6%），Vericel Corp自由现金流更多（$12.8M vs $11.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 10.8%）
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
PLPC vs VCEL — 直观对比
营收规模更大
PLPC
是对方的1.9倍
$92.9M
营收增速更快
VCEL
高出19.7%
3.6%
净利率更高
VCEL
高出20.1%
4.9%
自由现金流更多
VCEL
多$1.0M
$11.8M
两年增速更快
VCEL
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $173.1M | $92.9M |
| 净利润 | $8.4M | $23.2M |
| 毛利率 | 29.8% | 78.7% |
| 营业利润率 | 6.8% | 24.1% |
| 净利率 | 4.9% | 25.0% |
| 营收同比 | 3.6% | 23.3% |
| 净利润同比 | -19.3% | 17.3% |
| 每股收益（稀释后） | $1.72 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLPCVCEL
| Q4 25 | $173.1M | $92.9M | ||
| Q3 25 | $178.1M | $67.5M | ||
| Q2 25 | $169.6M | $63.2M | ||
| Q1 25 | $148.5M | $52.6M | ||
| Q4 24 | $167.1M | $75.4M | ||
| Q3 24 | $147.0M | $57.9M | ||
| Q2 24 | $138.7M | $52.7M | ||
| Q1 24 | $140.9M | $51.3M |
净利润PLPCVCEL
| Q4 25 | $8.4M | $23.2M | ||
| Q3 25 | $2.6M | $5.1M | ||
| Q2 25 | $12.7M | $-553.0K | ||
| Q1 25 | $11.5M | $-11.2M | ||
| Q4 24 | $10.5M | $19.8M | ||
| Q3 24 | $7.7M | $-901.0K | ||
| Q2 24 | $9.4M | $-4.7M | ||
| Q1 24 | $9.6M | $-3.9M |
毛利率PLPCVCEL
| Q4 25 | 29.8% | 78.7% | ||
| Q3 25 | 29.7% | 73.5% | ||
| Q2 25 | 32.7% | 73.7% | ||
| Q1 25 | 32.8% | 69.0% | ||
| Q4 24 | 33.3% | 77.6% | ||
| Q3 24 | 31.1% | 71.9% | ||
| Q2 24 | 31.9% | 69.5% | ||
| Q1 24 | 31.3% | 68.9% |
营业利润率PLPCVCEL
| Q4 25 | 6.8% | 24.1% | ||
| Q3 25 | 7.4% | 5.1% | ||
| Q2 25 | 10.1% | -3.2% | ||
| Q1 25 | 8.8% | -24.3% | ||
| Q4 24 | 10.5% | 24.5% | ||
| Q3 24 | 7.1% | -4.3% | ||
| Q2 24 | 8.1% | -11.5% | ||
| Q1 24 | 8.2% | -10.7% |
净利率PLPCVCEL
| Q4 25 | 4.9% | 25.0% | ||
| Q3 25 | 1.5% | 7.5% | ||
| Q2 25 | 7.5% | -0.9% | ||
| Q1 25 | 7.8% | -21.4% | ||
| Q4 24 | 6.3% | 26.3% | ||
| Q3 24 | 5.2% | -1.6% | ||
| Q2 24 | 6.8% | -8.9% | ||
| Q1 24 | 6.8% | -7.5% |
每股收益（稀释后）PLPCVCEL
| Q4 25 | $1.72 | $0.46 | ||
| Q3 25 | $0.53 | $0.10 | ||
| Q2 25 | $2.56 | $-0.01 | ||
| Q1 25 | $2.33 | $-0.23 | ||
| Q4 24 | $2.13 | $0.40 | ||
| Q3 24 | $1.54 | $-0.02 | ||
| Q2 24 | $1.89 | $-0.10 | ||
| Q1 24 | $1.94 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $137.5M |
| 总债务越低越好 | $38.3M | — |
| 股东权益账面价值 | $475.5M | $354.6M |
| 总资产 | $653.6M | $488.0M |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资PLPCVCEL
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
总债务PLPCVCEL
| Q4 25 | $38.3M | — | ||
| Q3 25 | $36.0M | — | ||
| Q2 25 | $31.8M | — | ||
| Q1 25 | $29.1M | — | ||
| Q4 24 | $20.8M | — | ||
| Q3 24 | $27.2M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $55.0M | — |
股东权益PLPCVCEL
| Q4 25 | $475.5M | $354.6M | ||
| Q3 25 | $466.3M | $321.9M | ||
| Q2 25 | $460.7M | $306.8M | ||
| Q1 25 | $435.8M | $295.5M | ||
| Q4 24 | $422.3M | $292.0M | ||
| Q3 24 | $429.0M | $257.5M | ||
| Q2 24 | $416.2M | $243.0M | ||
| Q1 24 | $413.4M | $233.9M |
总资产PLPCVCEL
| Q4 25 | $653.6M | $488.0M | ||
| Q3 25 | $644.6M | $453.3M | ||
| Q2 25 | $631.5M | $435.6M | ||
| Q1 25 | $592.5M | $424.6M | ||
| Q4 24 | $573.9M | $432.7M | ||
| Q3 24 | $592.0M | $390.4M | ||
| Q2 24 | $572.6M | $376.8M | ||
| Q1 24 | $586.1M | $356.7M |
负债/权益比PLPCVCEL
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.08× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.9M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $11.8M | $12.8M |
| 自由现金流率自由现金流/营收 | 6.8% | 13.8% |
| 资本支出强度资本支出/营收 | 5.9% | 2.4% |
| 现金转化率经营现金流/净利润 | 2.60× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $33.3M | $24.7M |
8季度趋势，按日历期对齐
经营现金流PLPCVCEL
| Q4 25 | $21.9M | $15.0M | ||
| Q3 25 | $18.9M | $22.1M | ||
| Q2 25 | $26.9M | $8.2M | ||
| Q1 25 | $5.7M | $6.6M | ||
| Q4 24 | $24.1M | $22.2M | ||
| Q3 24 | $9.4M | $10.2M | ||
| Q2 24 | $28.3M | $18.5M | ||
| Q1 24 | $5.8M | $7.2M |
自由现金流PLPCVCEL
| Q4 25 | $11.8M | $12.8M | ||
| Q3 25 | $8.3M | $19.5M | ||
| Q2 25 | $18.6M | $81.0K | ||
| Q1 25 | $-5.3M | $-7.6M | ||
| Q4 24 | $20.6M | $8.5M | ||
| Q3 24 | $5.8M | $-9.2M | ||
| Q2 24 | $24.6M | $1.8M | ||
| Q1 24 | $1.8M | $-6.8M |
自由现金流率PLPCVCEL
| Q4 25 | 6.8% | 13.8% | ||
| Q3 25 | 4.7% | 28.8% | ||
| Q2 25 | 10.9% | 0.1% | ||
| Q1 25 | -3.6% | -14.5% | ||
| Q4 24 | 12.3% | 11.2% | ||
| Q3 24 | 3.9% | -15.9% | ||
| Q2 24 | 17.7% | 3.4% | ||
| Q1 24 | 1.3% | -13.3% |
资本支出强度PLPCVCEL
| Q4 25 | 5.9% | 2.4% | ||
| Q3 25 | 6.0% | 3.9% | ||
| Q2 25 | 4.9% | 12.9% | ||
| Q1 25 | 7.4% | 27.0% | ||
| Q4 24 | 2.1% | 18.3% | ||
| Q3 24 | 2.4% | 33.5% | ||
| Q2 24 | 2.7% | 31.8% | ||
| Q1 24 | 2.8% | 27.3% |
现金转化率PLPCVCEL
| Q4 25 | 2.60× | 0.65× | ||
| Q3 25 | 7.21× | 4.35× | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 2.30× | 1.12× | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 3.02× | — | ||
| Q1 24 | 0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLPC
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
